TESSA™ technology is a novel, scalable, transfection-free manufacturing process for adeno-associated virus (AAV) and represents a major advancement in AAV manufacturing by improving AAV yields and particle quality. TESSA™ technology produces far more AAV than plasmid-based manufacturing, generating enough material to meet the growing healthcare demands for patients suffering from cancer and other life-threatening diseases.
As part of this collaboration, WuXi ATU will provide the materials, equipment, funding and training needed to further develop and commercialize TESSA™ technology in Singapore. BTI will bring its research expertise, facilities and access to its network of partners to support WuXi ATU in its research and development in cell and gene therapy in Singapore.
“We are delighted to launch this collaboration with that of Singapore Renowned Institute of Bioprocess Technology,” said David Chang, CEO of WuXi Advanced Therapies. “We hope that working together to develop and commercialize TESSA™ technology will be the first step in a long-term partnership.”
Doctor Koh Boon TongExecutive Director of A*STAR’s Bioprocessing Technology Institute, added, “With BTI’s extensive experience in bioprocess science and engineering, we are delighted to collaborate with WuXi ATU in the area of cell and gene therapy. progress and pursue R&D together. This is an important step. toward that of Singapore objective of being an innovative R&D center in biotherapeutic bioprocesses.”
About WuXi Advanced Therapies (WuXi ATU)
As the Advanced Therapies Business Unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Trial, Development, and Manufacturing Organization (CTDMO) that provides integrated platforms to transform the discovery, development, testing, manufacturing and the commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs worldwide. For more information, please visit https://www.advancedtherapies.com
About WuXi AppTec
As a global company with operations across Asia, Europeand North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discovery and deliver breakthrough treatments to patients. With its unique business models, WuXi AppTec’s end-to-end integrated services include CRDMO (Contract Research, Development and Manufacturing Organization) drug chemistry, biology discovery, preclinical testing and clinical research services, therapeutics cell and gene CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advanced healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2021 and its self-service platform empowers more than 5,800 employees in more than 30 countries to improve the health of those in need – and realize the vision that ” every medicine can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com
About A*STAR’s Bioprocessing Technology Institute
The Bioprocessing Technology Institute (BTI) is a research institute under A*STAR. Founded in 1990, BTI positions itself as that of Singapore mainstay of research and development for the biomanufacturing sector. BTI’s core capabilities span the entire bioprocess value chain, largely comprising product innovation, cell line development, media development, downstream processing, process development and scaling, and analytical science and technology. Through strategic partnerships and application-driven research, BTI seeks to create value and impact product markets, including biologics, cell and gene therapy, exosomes, vaccines, engineered tissues, process analysis technologies and cell culture systems. For more information about BTI, visit www.a-star.edu.sg/bti.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is that of Singapore leading public sector R&D agency. Through open innovation, we collaborate with our partners in the public and private sectors for the benefit of the economy and society. As a science and technology organization, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and improves lives by improving societal outcomes in healthcare, urban living and sustainability. A*STAR plays a key role in developing scientific talent and leaders for the research community and industry at large. A*STAR’s R&D activities extend from biomedical sciences to physical sciences and engineering, with research entities mainly located in Biopolis and Fusionopolis. For current news, visit www.a-star.edu.sg.
follow us on
Facebook | LinkedIn | Instagram | YouTube | Twitter
For media inquiries, please contact:
Executive Director, Brand and Corporate Communications
Tel: +86-21 2066 3111
E-mail: [email protected]
Yippee Min Ting
Deputy Head, Corporate Communications
Agency for Science, Technology and Research
Such. : +65 6517 1977
E-mail: [email protected]
SOURCE WuXi AppTec